Bowman-Birk soybean protease inhibitor as an anticarcinogen

Area of Science:

• Biochemistry
• Oncology
• Nutritional Science

Background:

• Epidemiological studies link vegetarian diets and seed consumption (maize, corn, beans) to reduced cancer risk.
• Protease inhibitors, abundant in seeds, are known to inhibit tumor promotion in vitro and in vivo.
• Dietary factors, including high-protein and high-fat diets, are associated with increased cancer occurrence.

Purpose of the Study:

• To investigate the stability and activity of soybean-derived Bowman-Birk inhibitor (BBI) during digestion.
• To determine the anticarcinogenic potential of BBI, specifically its effect on radiation-induced cellular transformation.
• To explore potential mechanisms of anticarcinogenesis by ingested protease inhibitors.

Main Methods:

• Rodent models were used to assess BBI survival and activity through the digestive tract.
• In vitro assays were employed to evaluate the radioprotective effect of BBI on cellular transformation.
• Analysis of fecal excretion was performed to identify BBI-protease complexes.

Main Results:

• Bowman-Birk inhibitor (BBI) from soybeans demonstrated stability and activity in the small intestine after oral ingestion in rodents.
• BBI effectively formed complexes with intestinal proteases (trypsin, chymotrypsin), largely excreted in feces.
• BBI specifically inhibited radiation-induced cellular transformation in vitro, indicating a radioprotective effect.

Conclusions:

• Ingested protease inhibitors, such as BBI, can survive gastrointestinal digestion and exert biological effects.
• Protease inhibitors may possess anticarcinogenic properties through direct actions, like radioprotection, and indirect mechanisms, potentially involving protein absorption modulation.
• Further research is needed to elucidate the relative contributions of direct and indirect mechanisms in the anticarcinogenic activity of protease inhibitors.